Streetbeat News

Stock Prices

DIS

Goldman Sachs analyst Michael Ng maintains a Buy rating on Disney, citing strong box office and streaming growth as potential offsets to weaknesses in Experiences and linear segments. Ng forecasts Disney's Q4 earnings to exceed consensus estimates, driven by subscriber growth and price increases in streaming.

Portfolio Pulse from Chris Katje

September 25, 2024 | 8:09 pm

CNXC

Concentrix shares are experiencing a decline after the company reported mixed financial results for the third quarter.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:09 pm

LUMO

Lumos Pharma's updated analysis from its Phase 2 OraGrowtH210 trial will be presented at the APPES 2024 meeting, focusing on LUM-201 for Pediatric Growth Hormone Deficiency.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:08 pm

LAES

SEALSQ (NASDAQ:LAES) reported a significant decline in its financial performance for the first half of the year, with EPS dropping from $(0.06) to $(0.37) and sales falling from $14.75 million to $4.83 million year-over-year.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:07 pm

AOUT

American Outdoor Brands has announced a stock repurchase program, authorizing the buyback of up to $10 million of its common stock from October 1, 2024, to September 30, 2025.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:06 pm

MDXH

MDxHealth has announced a $40 million offering of ordinary shares, which could impact its stock price and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:06 pm

FUL

H.B. Fuller reported Q3 2024 earnings per share of $1.13, missing the analyst estimate of $1.23. Sales were $917.927 million, below the expected $944.252 million, but up 1.92% from last year.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:06 pm

MU

Micron shares are trading higher after the company reported better-than-expected Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:04 pm

ABVX

Abivax announced promising preclinical results for its combination therapy of obefazimod and etrasimod in treating inflammatory bowel disease. The study showed significant improvements in disease markers, suggesting potential for future development.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:04 pm

MU

Micron Technology reported its Q4 2024 earnings, with adjusted EPS of $1.18 beating the estimate of $1.13, and sales of $7.750 billion surpassing the expected $7.635 billion.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 8:02 pm